Inovio Pharmaceuticals Inc. (INO)

4.23
0.01 0.24
NASDAQ : Health Technology
Prev Close 4.22
Open 4.26
Day Low/High 4.22 / 4.28
52 Wk Low/High 3.76 / 9.86
Volume 26.55K
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 90.30M
Market Cap 379.24M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stocks Under $10 Weekly Summary

We exited one position and added to another as volatility returned to the stock market last week.

Stocks Under $10 Weekly Summary

It was a mixed week for the portfolio as we trimmed one position and added to the Bullpen.

Why We Added JetPay to the Bullpen

This Berwyn, Pennsylvania firm has interesting prospects.

First Week of March 16th Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the March 16th expiration.

Trimming a Biotech Position

I no longer trust the stock of Inovio Pharmaceuticals, as an investor.

Stocks Under $10 Weekly Summary

Last week, we closed a position for a large gain and used some of the proceeds to start a small stake in a fracking and desalination name.

Inovio's Co-Founder Along With Its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents For 2016

Inovio's Co-Founder Along With Its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents For 2016

Dr. David B. Weiner, Inovio co-founder, and Dr. Jian Yan, Lead Antigen Designer, recognized for their innovative medical and scientific research which led to more than 20 granted U.S. patents in one year

Stocks Under $10 Weekly Summary

We added two new positions to the portfolio last week.

Stocks Under $10 Weekly Summary

Despite a shortened trading week, we made a series of moves, including initiating a position in GSV Capital.

Inovio Receives Milestone Payment From MedImmune As MEDI0457 And Checkpoint Inhibitor Combination Trial In Head And Neck Squamous Cell Cancer Advances To Phase 2

Inovio Receives Milestone Payment From MedImmune As MEDI0457 And Checkpoint Inhibitor Combination Trial In Head And Neck Squamous Cell Cancer Advances To Phase 2

First efficacy trial to evaluate Inovio's cancer immunotherapy targeting HPV in combination with durvalumab

Trimming a Biotech; Adding 2 Bullpen Names

We'll sell some Inovio Pharma on recent strength and put 2 'pot names,' Kush Bottles and Corbus Pharmaceuticals, in the Bullpen.

Stocks Under $10 Weekly Summary

During a quiet week for the market, we added to two positions and trimmed three others.

Inovio Enters License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio Enters License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio to receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on sales

Adding to and Trimming Different Biotechs

We will buy more AcelRx Pharmaceuticals and sell shares of Inovio Pharmaceuticals as we close out 2017.

Stocks Under $10 Weekly Summary

During another busy week, we rang the register and exited our position in Amplify, trimmed another name twice and scaled into a recent addition.

Interesting INO Put And Call Options For August 2018

Interesting INO Put And Call Options For August 2018

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.

Stocks Under $10 Weekly Summary

Last week was a busy one for the portfolio, as we made a number of trades and saw outsized gains in several positions.

Selling a Chunk of a Biotech and Upgrading a Stock

We're reducing our position in Inovio Pharmaceuticals and raising our rating on Hudson Technologies.

Stocks Under $10 Weekly Summary

We bought into some tech names last week as a rotation occurred in the sector.

Inovio Pharmaceuticals Promotes Dr. Laurent Humeau To Senior Vice President, Research & Development

Inovio Pharmaceuticals Promotes Dr. Laurent Humeau To Senior Vice President, Research & Development

New strategic position will guide product discovery  and scientific collaborations

Inovio Pharmaceuticals Appoints Wendy Yarno To Its Board Of Directors

Inovio Pharmaceuticals Appoints Wendy Yarno To Its Board Of Directors

Former Chief Marketing Officer at Merck Also Brings Women's Health Management Expertise

Stocks Under $10 Weekly Summary

For the second week in a row, we initiated a new position, this time in a security tech name.

Inovio's Further Analysis Of VGX-3100 Phase 2b Data Reveals Immune Correlates And Biomarker Signatures That Predicted Clinical Efficacy

Inovio's Further Analysis Of VGX-3100 Phase 2b Data Reveals Immune Correlates And Biomarker Signatures That Predicted Clinical Efficacy

Inovio continues to investigate pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product

Stocks Under $10 Weekly Summary

We initiated a new position for the portfolio during the shortened holiday trading week.

TheStreet Quant Rating: D (Sell)